Robert Mcmahon

Robert "Bob" W. McMahon is a veteran healthcare-industry finance executive with roughly 34 years of experience. He holds a bachelor's degree in Finance from the University of Florida and an MBA in Finance from the University of Central Florida, and is a Certified Management Accountant (CMA). He began his career at Harris Corporation in Florida before joining Johnson & Johnson in 1993, where he spent more than 20 years in progressively senior financial leadership roles spanning corporate finance, financial planning and analysis, portfolio optimization, enterprise valuation, and divestiture management. His most senior J&J role was Worldwide Vice President of Finance and Business Development for Ortho Clinical Diagnostics, part of J&J's Medical Device and Diagnostics group.

From May 2014 to August 2018, McMahon served as Chief Financial Officer of Hologic, Inc., a medical technology company focused on women's health. In August 2018 he joined Agilent Technologies, becoming Senior Vice President and CFO on September 1, 2018. At Agilent he was responsible for Finance, Audit, Treasury, Tax, Investor Relations, and later IT and procurement, and was widely credited by analysts with maintaining Agilent's financial discipline over his seven-year tenure.

On July 11, 2025, McMahon notified Agilent of his intention to resign, stepping down effective July 31, 2025, citing a relocation to the U.S. East Coast for family reasons. Agilent stated the departure involved no disagreement over accounting practices, financial statements, internal controls, or operations, and named corporate controller Rodney Gonsalves as interim CFO. On July 21, 2025, West Pharmaceutical Services announced McMahon as its incoming Senior Vice President and CFO, effective August 4, 2025.

Beyond his executive roles, McMahon has served since July 31, 2023 as an independent director on the Board of Directors of OraSure Technologies, Inc. (a Class II Director, initial term expiring at the company's 2026 Annual Meeting), where he brings deep diagnostics and corporate-finance expertise.

• This is not a venture/angel investor. The stub's "Angel Investors / Seed Round" classification is not supported by any public source. McMahon's capital-allocation activity is that of a corporate CFO (overseeing M&A, divestitures, treasury, and portfolio optimization) and a public-company board director — not personal early-stage checks.
• Domain expertise: Deep specialization in healthcare, life-sciences tools, diagnostics, and medical devices — the sectors across J&J/Ortho Clinical Diagnostics, Hologic, Agilent, OraSure, and West Pharmaceutical.
• Financial discipline: Analysts noted he "continued the strength of financial discipline at Agilent," reflecting a focus on margin management, guidance reliability, and disciplined capital deployment.
• Corporate development orientation: His background emphasizes business development, divestiture management, enterprise valuation, and portfolio optimization — the levers a strategic CFO uses rather than an angel investor's thesis.